Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.

Hesketh PJ, Aapro M, Street JC, Carides AD.

Support Care Cancer. 2010 Sep;18(9):1171-7. doi: 10.1007/s00520-009-0737-9. Epub 2009 Sep 12.

PMID:
19756774
[PubMed - indexed for MEDLINE]
2.

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.

Eur J Cancer. 2004 Feb;40(3):403-10.

PMID:
14746859
[PubMed - indexed for MEDLINE]
3.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

PMID:
12784346
[PubMed - indexed for MEDLINE]
Free Article
4.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
[PubMed - indexed for MEDLINE]
Free Article
5.

Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.

Navari RM.

Expert Rev Anticancer Ther. 2004 Oct;4(5):715-24. Review.

PMID:
15485308
[PubMed - indexed for MEDLINE]
6.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ.

Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1.

PMID:
19568773
[PubMed - indexed for MEDLINE]
7.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. Epub 2003 Oct 14.

PMID:
14559891
[PubMed - indexed for MEDLINE]
Free Article
8.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J.

J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7.

PMID:
21383291
[PubMed - indexed for MEDLINE]
Free Article
9.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

PMID:
12712486
[PubMed - indexed for MEDLINE]
Free Article
10.

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.

Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y, Huang C, Chang J, Song X, Liang J, Liang H, Bai C, Yu S, Chen J, Wang J, Pan H, Chitkara DK, Hille DA, Zhang L.

Support Care Cancer. 2014 Apr;22(4):979-87. doi: 10.1007/s00520-013-2043-9. Epub 2013 Nov 26.

PMID:
24276953
[PubMed - indexed for MEDLINE]
11.

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.

Eur J Cancer. 2005 Jun;41(9):1278-85.

PMID:
15939263
[PubMed - indexed for MEDLINE]
12.

Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.

Annemans L, Strens D, Lox E, Petit C, Malonne H.

Support Care Cancer. 2008 Aug;16(8):905-15. Epub 2007 Oct 27.

PMID:
17965891
[PubMed - indexed for MEDLINE]
13.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
[PubMed - indexed for MEDLINE]
14.

[Treatment of tumor therapy-induced nausea and vomiting].

Pikó B, Bassam A.

Magy Onkol. 2009 Mar;53(1):39-45. doi: 10.1556/MOnkol.53.2009.1.6. Review. Hungarian.

PMID:
19318325
[PubMed - indexed for MEDLINE]
Free Article
15.

Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.

Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM.

Eur J Cancer. 2003 Jul;39(10):1395-401.

PMID:
12826042
[PubMed - indexed for MEDLINE]
16.

Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.

Massaro AM, Lenz KL.

Ann Pharmacother. 2005 Jan;39(1):77-85. Epub 2004 Nov 23. Review.

PMID:
15562136
[PubMed - indexed for MEDLINE]
17.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Navari RM.

J Support Oncol. 2003 Jul-Aug;1(2):89-103. Review.

PMID:
15352652
[PubMed - indexed for MEDLINE]
19.

[Retrospective analysis of antiemetic effect in patients receiving cisplatin].

Yonemura M, Akita T, Suzuki S, Gotoh K, Tahara M, Ohtsu A, Ohe Y, Mouri K, Izumi K.

Gan To Kagaku Ryoho. 2011 Jul;38(7):1155-8. Japanese.

PMID:
21772101
[PubMed - indexed for MEDLINE]
20.

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.

Warr DG, Street JC, Carides AD.

Support Care Cancer. 2011 Jun;19(6):807-13. doi: 10.1007/s00520-010-0899-5. Epub 2010 May 13.

PMID:
20461438
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk